The Cushing's Syndrome Diagnostic and Treatment Market is expected to grow from USD 0.40 billion in 2025 to USD 0.56 billion in 2030, at a CAGR of 6.9%.
Cushing’s disease is a condition characterised by the presence of excess steroid hormone “cortisol”’ or stress hormone in blood vessels and is caused by improper functioning of the pituitary glands, which are responsible for secreting adrenocorticotropic hormone (ACTH). ACTH stimulates the adrenal glands (located on top of the kidneys) to produce cortisol. Typical symptoms of Cushing’s syndrome are weight gain, the appearance of pink or purple stretch marks, thinning, and easily bruised skin. and occasionally type 2 diabetes. Treatment includes reducing the use of corticosteroids, surgery, and medications.
The market is expected to surge in the coming years, due to the rise in the number of Cushing syndrome cases worldwide. In the United States, according to the American Association of Neurological Surgeons, an estimated 10-15 per million people are affected annually. Moreover, pituitary adenomas, which are a major cause of Cushing disease, usually account for over 70% of total cases in adults and around 60% of cases in adolescents and children. According to the data given by the European Union, the prevalence rate of endogenous Cushing syndrome is around 1/26,000 worldwide, and in the European Union, it has a yearly incidence of 1/1,4000,000 with an extraordinary peak incidence at 25-40 years of age. These trends and developments are expected to spur the market’s growth in the coming years.
Major companies have been making significant developments in the market. With the rise in the number of Cushing syndrome diseases, the demand for novel treatment and diagnostic solutions is expected to surge. This has led to an increase in investment from various firms worldwide.
In March 2020, the United States Food and Drug Administration announced that it had approved Isturis oral tablets specifically for adults with Cushing's disease, who have undergone the surgery, but still have the disease, or cannot undergo pituitary gland surgery. The FDA had approved this novel drug based on the drug's study among 137 adult patients. The overall test results and study were positive. The approval had been granted to a major player, Novartis.
In March 2021, PGI doctors announced that they had developed a technique to treat Cushing syndrome. The doctors had developed a technique to locate the tumour in the pituitary gland, which has been a major cause of Cushing syndrome. The technique has been named Ga-68 CRH PET-CT. This development is expected to have a positive impact on the market.
In May 2021, Sparrow Pharmaceuticals, one of the major players in the market, announced that it had been planning to launch a novel Phase 2 clinical trial to assess the overall effectiveness and safety of lead small molecule, and investigational HSD-1 inhibitor, also known as SPI-62, in people suffering from Cushing's syndrome. The company had stated that the novel trial had been expected to open later in 2021, and it would enrol people with Cushing syndrome who have at least one of the following conditions: hyperlipidemia, impaired glucose tolerance, and type 2 diabetes.
In May 2021, the FDA announced that it had accepted a review of a novel drug application for the respective steroidogenesis inhibitor for the respective treatment of endogenous Cushing's syndrome. Major companies have welcomed this decision. Strongbridge Biopharma, one of the major players in the market, had stated that they had been pleased with the FDA's acceptance and approval for the filing of the Recorlav novel drug application. This development is expected to play a major role in the market’s growth in the coming years.
Surgery is expected to have a major share in the market.
There are several ways and methods to treat Cushing’s syndrome. Surgery is expected to have a major share of the market growth, as most patients have been opting for surgical procedures and methods globally. If the major cause of the problem is the tumour, then the doctor recommends a complete surgical removal. Hospitals have been spending a significant sum of capital to develop novel surgical procedures worldwide. For instance, in India, Apollo Hospitals Enterprise Ltd. offers surgical procedures and methods for its patients. The hospitals, to register more patients, have been investing a significant sum of capital into the adoption of novel and new machinery and equipment. The growth of the e-Health and online sectors is also expected to have a positive impact on the market
Novartis
Corcept Therapeutics Inc.
StrongBridge Biopharma
Orphagen Pharmaceuticals Inc.
HRA Pharma
| Report Metric | Details |
|---|---|
| Total Market Size in 2025 | USD 0.40 billion |
| Total Market Size in 2030 | USD 0.56 billion |
| Forecast Unit | Billion |
| Growth Rate | 6.9% |
| Study Period | 2020 to 2030 |
| Historical Data | 2020 to 2023 |
| Base Year | 2024 |
| Forecast Period | 2025 – 2030 |
| Segmentation | Diagnostic Test, Treatment, Geography |
| Geographical Segmentation | North America, South America, Europe, Middle East and Africa, Asia Pacific |
| Companies |
|